Fascination About GW7647
All enrolled patients who received a minimum of just one dose of zosuquidar or placebo in the course of induction ended up monitored for the occurrence of adverse functions (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse events had been connected with the period of prolonged and considerable myelosuppression as is predict